News

Press Release: October 11, 2017

Relburn-Metabolomics to Present Developments in Lead Programs for NASH and Gout

 

Press Release: October 6, 2017

Relburn-Metabolomics Appoints Renowned Experts in Nonalcoholic Steatohepatitis (NASH) to its Scientific Advisory Board

 

Press Release: May 19, 2017

Relburn-Metabolomics Announces a Second Drug Development Program in a Highly Prevalent Liver Disease:
Company to Present at NJ BIO Partnering Conference on May 23, 2017

 

Press Release: October 17, 2016

Relburn-Metabolomics Files Patents on Bifunctional Nanomolar Inhibitors of Gout Target Enzymes:
Company to Present at BIO Investor Forum in San Francisco October 18, 2016

 

Press Release: August 1, 2016

Relburn-Metabolomics Files Fourth Patent for its Anti-Gout Drug Portfolio:
Initial Portfolio Patent Also Receives U.S. Notice of Allowance

 

Press Release: October 20, 2015

Relburn-Metabolomics to Outline Research Progress at BIO Investor Forum

 

Press Release: June 9, 2015

Relburn-Metabolomics to Present at BIO International 2015

 

Press Release: January 7, 2015

Relburn-Metabolomics to Present at Biotech Showcase 2015

 

Press Release: October 6, 2014

Relburn-Metabolomics to Report Scientific Progress and Clinical Plans for Anti-Gout Program at Two Major Conferences

Abstract

Press Release: June 3, 2014

Relburn-Metabolomics to Report Clinical and Scientific Progress in Anti-Gout Program at the European Congress on Rheumatology

Abstract

Presentation

Press Release: January 7, 2014

Relburn-Metabolomics to Outline Clinical Development Plans for Lead Anti-Gout Product